Supplementary Materials

Anticancer Acridones, Part 2—Acronycine-Type Derivatives Modified with 2,5-Dihydro-1,2,4-Triazine Moiety: Synthesis and In Vitro Evaluation

Andrey A. Zonov [1], Ramil F. Fatykhov [1], Igor A. Khalymbadzha [1,2,*], Ainur D. Sharapov [1,3], Anastasia P. Potapova [1], Ilya I. Butorin [1], Vsevolod V. Melekhin [1], Anastasia V. Paramonova [1] and Emiliya V. Nosova [1]

[1] Department of Organic and Biomolecular Chemistry, Ural Federal University, 620002 Yekaterinburg, Russia; rf.fatykhov@urfu.ru (R.F.F.); a.d.sharapov@urfu.ru (A.D.S.); a.p.potapova@urfu.ru (A.P.P.); iibutorin@urfu.ru (I.I.B.); v.v.melekhin@urfu.ru (V.V.M.); a.v.paramonova@urfu.ru (A.V.P.)
[2] Research Center for Translational Medicine, Sirius University of Science and Technology, Olympic Ave. 1, 354340 Sochi, Russia
[3] Department of Biochemistry, Ural State Medical University, Repina 3, 620028 Yekaterinburg, Russia
* Correspondence: i.a.khalymbadzha@urfu.ru

Table of Contents

1. List of Tables

Table S1. Cytotoxic activity (IC_{50} ± SE) and Selectivity Index (SI) of compounds against the proliferation of human glioblastoma cells (A172,), human embryonic kidney 293 cells (HEK-293) and breast cancer cells (Hs578T), μM

	Compound	Cell lines				
		HEK-293	A172		Hs578T	
		IC_{50}	IC_{50}	SI	IC_{50}	SI
1	**9a**	8.03620 ± 0.24806	8.28275 ± 0.95078	0.97	7.5256 ± 1.8346	1.07
2	**9b**	38.810 ± 3.852	27.2619 ± 6.6416	1.42	7.7007 ± 1.3775	5.04
3	**9d**	51.8956 ± 4.8364	16.6082 ± 1.4763	3.12	17.6868 ± 1.8699	2.93
4	**9e**	32.636 ± 1.393	21.8508 ± 1.5509	1.49	8.4487 ± 1.7620	3.86
5	**9f**	2.28125 ± 0.18179	5.15274 ± 0.14922	0.44	16.0848 ± 2.0791	0.14
6	**9g**	**26.1177 ± 2.2527**	**3.44063 ± 0.16051**	**7.59**	8.5523 ± 1.3459	3.05
7	**9h**	19.0974 ± 2.6592	39.0126 ± 2.9821	0.49	28.4012 ± 5.0529	0.67
8	**10**	31.8696 ± 4.8348	21.8140 ± 1.6059	1.46	42.6012 ± 5.5749	0.75
9	Cisplatin	6.86973 ± 0.57844	1.55929 ± 0.08872	4.41	9.5817 ± 2.7556	0.72

Table S2. Analysis of the data showing percentage of late and early apoptotic glioblastoma cells after 72 h treatment with **9g** compound and cisplatin at IC_{50} concentration

Percentage of cells	Compound		
	Intact	Cisplatin	**3g**
AnV-/PI-	95	50	66
AnV-/PI+	5	12	20
AnV+/PI-	0	24	6
AnV+/PI+	0	14	8

2. List of Figures

Figure S32. IR spectrum of **9h**.

Figure S33. Concentration-viability response curve of heptafluorobutyric acid on A172 cells, mean ± SD.

Figure S34. Concentration-viability response curve of heptafluorobutyric acid on HEK-293 cells, mean ± SD.



Figure S1. [1]H NMR spectrum of **9a.**



Figure S2. [13]C NMR spectrum of **9a.**



Figure S3. ^{19}F NMR spectrum of **9a.**



Figure S4. IR spectrum of **9a.**



Figure S5. ^{1}H NMR spectrum of **9b.**



Figure S6. ^{13}C NMR spectrum of **9b.**



Figure S7. ^{19}F NMR spectrum of **9b.**



Figure S8. IR spectrum of **9b.**



Figure S9. ^{1}H NMR spectrum of **9c.**



Figure S10. ^{13}C NMR spectrum of **9c.**



Figure S11. ^{19}F NMR spectrum of **9c.**



Figure S12. IR spectrum of **9c.**



Figure S13. [1]H NMR spectrum of **9d.**



Figure S14. [13]C NMR spectrum of **9d.**



Figure S15. ^{19}F NMR spectrum of **9d.**



Figure S16. IR spectrum of **9d.**



Figure S17. [1]H NMR spectrum of **9e.**



Figure S18. [13]C NMR spectrum of **9e.**



Figure S19. ^{19}F NMR spectrum of **9e.**



Figure S20. IR spectrum of **9e.**



Figure S21. ^{1}H NMR spectrum of **9f.**



Figure S22. ^{13}C NMR spectrum of **9f.**



Figure S23. ^{19}F NMR spectrum of **9f.**



Figure S24. IR spectrum of **9f.**



Figure S25. ^{1}H NMR spectrum of **9g.**



Figure S26. ^{13}C NMR spectrum of **9g.**



Figure S27. ^{19}F NMR spectrum of **9g.**



Figure S28. IR spectrum of **9g.**



Figure S29. [1]H NMR spectrum of **9h.**



Figure S30. [13]C NMR spectrum of **9h.**



Figure S31. ^{19}F NMR spectrum of **9h.**



Figure 32. IR spectrum of **9h.**



Figure S33. Concentration-viability response curve of heptafluorobutyric acid on A172 cells, mean ± SD.



Figure S34. Concentration-viability response curve of heptafluorobutyric acid on HEK-293 cells, mean ± SD.